Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

Alessandra Cesano, M.D., Ph.D., Cheryl L Willman, MD, Kenneth J. Kopecky, PhD, Urte Gayko, Ph.D., Santosh Putta, Ph.D., Brent Louie, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., David Spellmeyer, PhD, Carol Marimpietri, James Hackett, Ph.D., Jing Shi, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Larry D Cripe, MD, Susan K. Atwater, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD

Blood (2012) 120 (21): 2489.

https://doi.org/10.1182/blood.V120.21.2489.2489

Published: 2012

Journal Articles

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Alessandra Cesano, M.D., Ph.D., Santosh Putta, Ph.D., Kavita Mathi, MD, David B. Rosen, PhD, Urte Gayko, Ph.D., Rachael E. Hawtin, Ph.D., Larry D Cripe, MD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Elisabeth Paietta, Ph.D.

Blood (2011) 118 (21): 2512.

https://doi.org/10.1182/blood.V118.21.2512.2512

Published: 2011

Journal Articles

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Norman J. Lacayo, MD, Todd A. Alonzo, PhD, Urte Gayko, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., Santosh Putta, Ph.D., James Hackett, Ph.D., Aileen Cleary Cohen, MD, PhD, Robert B. Gerbing, M.A., Gary V Dahl, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, Ph.D.

Blood (2011) 118 (21): 3544.

https://doi.org/10.1182/blood.V118.21.3544.3544

Published: 2011

Journal Articles

Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling

David B. Rosen, PhD, Santosh Putta, Ph.D., Urte Gayko, Ph.D., Alessandra Cesano, MD, Larry Cripe, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Hajime Uno, PhD, Martin S. Tallman, MD, Elisabeth Paietta, PhD

Blood (2010) 116 (21): 2739.

https://doi.org/10.1182/blood.V116.21.2739.2739

Published: 2010

Journal Articles

Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421

Norman J. Lacayo, MD, Aileen Cohen, Ph.D., M.D., Matt Westfall, Ph.D., Alan Lackey, MS, Xiaohua (Robert) Xin, Ph.D., M.D., Urte Gayko, Ph.D., Santosh Putta, Ph.D., Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Todd A. Alonzo, PhD, Robert J. Arceci, MD, PhD, Yaddanapudi Ravindranath, MD, Gary Van Houten Dahl, MD, Alessandra Cesano, MD

Blood (2010) 116 (21): 954.

https://doi.org/10.1182/blood.V116.21.954.954

Published: 2010

Journal Articles

Sample Cryopreservation Does Not Affect Functional Read Outs In SCNP Assays: Implications for Biomarker Development

Alessandra Cesano, MD, Jason R Gotlib, MD, MS, Norman J. Lacayo, MD, Santosh Putta, Ph.D., Alan Lackey, MS, Urte Gayko, Ph.D., Steven M. Kornblau, MD

Blood (2010) 116 (21): 4843.

https://doi.org/10.1182/blood.V116.21.4843.4843

Published: 2010

Journal Articles

Specimen Source (BM or PB) Does Not Affect Proteomic Signaling In Patients with AML and Circulating Blasts

Alessandra Cesano, MD, David B. Rosen, PhD, Santosh Putta, Urte Gayko, Ph.D., Larry Cripe, MD, Zhuoxin Sun, PhD, Hajime Uno, PhD, Mark R. Litzow, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD

Blood (2010) 116 (21): 2693.

https://doi.org/10.1182/blood.V116.21.2693.2693

Published: 2010

Journal Articles

Single-Cell Network Profiliing (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML)

Alessandra Cesano, MD, Santosh Putta, Ph.D., Urte Gayko, Ph.D., James Hackett, Ph.D., David B. Rosen, PhD, Larry Cripe, MD, Zhuoxin Sun, PhD, Hajime Uno, PhD, Mark R. Litzow, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD

Blood (2010) 116 (21): 2695.

https://doi.org/10.1182/blood.V116.21.2695.2695

Published: 2010

NARROW

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling

Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421

Sample Cryopreservation Does Not Affect Functional Read Outs In SCNP Assays: Implications for Biomarker Development

Specimen Source (BM or PB) Does Not Affect Proteomic Signaling In Patients with AML and Circulating Blasts

Single-Cell Network Profiliing (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only